Hanmi R&D becomes stronger through cooperation with partners.
- efocipegtrutide (LAPSTriple agonist)
- sonefpeglutide (LAPSGLP-2 analog)
- efpegerglucagon (LAPSGlucagon analog)
- HM97662 (EZH1/2 inhibitor)
- BH3120 (PD-L1/4-1BB BsAb)
- HM15275 (LA-GLP/GIP/GCG)
- HM16390 (LAPSIL-2 analog)
- HM17321 (LA-UCN2)
- HM101207 (SOS1 inhibitor)
- LAPS Glucagon Combo
HM17321 (LA-UCN2)
Overview
Description
Despite efficient weight loss, incretin therapy results in significant lean mass loss and impaired weight loss quality (WLQ). So, the development of novel therapy for WLQ improvement is of great interest in recent obesity market. To achieve this ultimate goal, Hanmi initiates LA-UCN2 project. HM17321 is a novel obesity drug discovered by combining Hanmi's scientific expertise with the modern AI and structural modeling technologies, and is a corticotropin-releasing factor 2 (CRF2) receptor selective urocortin-2 (UCN2) analog with a long-acting technology.
In nonclinical studies, HM17321 has demonstrated significant weight, fat mass reduction and lean mass increase in obese animal model, confirming its potential to improve a variety of metabolic conditions, including cardiovascular disease (CVD). By providing high quality obesity management and additional metabolic benefits, HM17321 is poised to be a game-changer in the rapidly growing obesity market.
In nonclinical studies, HM17321 has demonstrated significant weight, fat mass reduction and lean mass increase in obese animal model, confirming its potential to improve a variety of metabolic conditions, including cardiovascular disease (CVD). By providing high quality obesity management and additional metabolic benefits, HM17321 is poised to be a game-changer in the rapidly growing obesity market.
Optimized UCN2 analog for high quality weight management
- Analog discovered using Hanmi's AI, structural modeling and scientific know-how
- Optimized CRF2 receptor selectivity to reduce fat mass and increase lean mass simultaneously
- Positive effects on cardiovascular diseases such as heart failure and metabolic diseases such as type 2 diabetes
- Significant weight, fat loss and lean mass gains with monotherapy alone
- Combination with other incretin obesity drugs, such as GLP-1, provides patients with better options
*For illustrative purposes
Obese patients who take incretin-based obesity treatments may lose weight, but they may appear saggy due to a lack of muscle tone. However, after administration of LA-UCN2, not only do they lose weight, but their body appears more toned and firm.
This is an illustration of the positive effects on muscle, fat, and heart below by inducing the CRF1 receptor to decrease activity and CRF2 receptor to maintain activity
-
Muscle
- Muscle hypertrophy
- Metabolic/functional improvement
-
Fat
- Fat mass reduction
- High quality weight loss
-
Heart
- Improved cardiovascular function
- Cardiac protection
Clinical Development
- A phase 1 study is currently ongoing in the US NCT07219589
Publications